May Do

Quick links to important sections

May Do

Treatment option: Zits, Blackheads, Acne Vulgaris

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of May Do

Property Description
Active ingredient Adapalene (INN)
Form Topical preparations (Gel, Cream, Lotion, Solution)
Pharmacological class Third-Generation Synthetic Retinoid
Common use Foundational management of acne characteristics
Origin Synthetic (Naphthoic acid derivative)

May Do: Definition and Composition

May Do is a trade name for a topical medicine containing the widely prescribed active ingredient, Adapalene. Adapalene is a synthetic compound derived from naphthoic acid, which is recognized for its stability and targeted action. The medication is designed for topical administration and is supplied in various physical forms, including a fast-absorbing gel, an emollient cream, a lighter lotion, or a solution vehicle base. May Do is typically available as a single-agent product, though Adapalene itself is found in combination products under other brands.

Classification as a Topical Retinoid Agent

The active substance Adapalene is scientifically classified as a third-generation synthetic retinoid, a specific subgroup of compounds related to Vitamin A. Its high-level designation is as a Topical Acne Agent. A differentiating factor for Adapalene is its selective binding to the Retinoic Acid Receptors beta and gamma. This targeted mechanism distinguishes it from less selective earlier-generation retinoids. This precise action provides effective management for users aged 12 years and older.

Core Purpose and General Action Principles

The principal purpose of May Do is to support the normalized functioning of the skin barrier and address the foundational characteristics of the target skin condition. It is widely applied for its potent comedolytic and anticomedogenic effects, actively helping to break down existing pore blockages and inhibiting the formation of new ones. Adapalene also provides a notable anti-inflammatory action. This comprehensive effect provides a targeted therapeutic foundation for reducing both visible imperfections and the underlying inflammation.

Regulatory References

  1. Adapalene - StatPearls
  2. Adapalene Drug Information

What side effects are possible with May Do?

Possible side effects and safety information

The official safety profile for topical Adapalene (May Do) is primarily defined by local application site reactions, as documented in government regulatory labeling. Adverse reactions are classified by frequency to communicate the established risk characteristics.

Frequency-Classified Adverse Reactions

The most frequent effects are classified as Common in regulatory documents (1/100 to < 1/10), which typically involve the site of application. These reactions include skin dryness, skin irritation, a burning sensation, and erythema (redness).

Reactions classified as Uncommon (1/1,000 to < 1/100) include contact dermatitis, general skin discomfort, pruritus (itching), scaling, and headache. Post-marketing reports also document reactions of Not Known frequency, such as angioedema, facial swelling, allergic contact dermatitis, and photophobia.

Time-Related Safety Patterns

Official labeling notes that the intensity of local reactions, such as irritation and dryness, is generally expected to peak during the first one to two weeks of treatment and subsequently tends to subside with continued use.

Serious and Population-Specific Safety

Potentially serious reactions, although rare, include signs of hypersensitivity like angioedema and facial swelling, which affect the Immune System Disorders class. Safety statements specifically address use in vulnerable groups: the product is generally contraindicated during pregnancy, and caution is advised during breastfeeding due to the unknown systemic absorption.

Safety Restrictions and Limitations

Regulatory documentation mandates minimizing or avoiding exposure to sunlight and artificial UV light (such as sunlamps) while using this medication due to photosensitivity risk. Furthermore, the product should not be applied to eczematous skin, cuts, or abrasions. Caution is necessary when using other topical products that may be irritating due to the potential for additive effects.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for May Do (Adapalene) detail distinct consequences based on the route of exposure. The primary documented form of overdose involves excessive topical application, which results in local adverse effects. Overuse is noted to cause marked redness (erythema), pronounced scaling or peeling, discomfort, and excessive dryness at the application site. Regulatory guidance for this common scenario is to temporarily suspend use or reduce the frequency of application until the local symptoms fully subside.


Exposure Scenario Documented Manifestation Regulator-Mandated Action
Excessive Topical Use Local skin reactions (redness, peeling, dryness) Temporarily suspend use or reduce frequency.
Accidental Oral Ingestion Theoretical risk of systemic effects (Hypervitaminosis A syndrome) Seek immediate medical attention or Poison Control.

Systemic toxicity following topical application is stated to be highly unlikely due to the minimal absorption of the product through the skin. However, in the event of suspected accidental oral ingestion, the prescribing information advises seeking immediate medical attention or contacting a certified Poison Control Center immediately. This action is mandated due to the theoretical potential for systemic effects similar to those seen with massive oral intake of Vitamin A. Treatment for systemic overdose is defined as symptomatic and supportive, as official documents state that no specific antidote is known for Adapalene.

Therapeutic Uses of May Do

What May Do Treats: Main Uses and Benefits

May Do Treats is commonly used to provide supportive relief, assisting individuals to cope more steadily with disruptive symptom manifestations across common conditions. The medication is generally used in therapeutic domains involving pain, fever, and inflammation.


May Do Treats plays a role in managing symptoms related to physical discomfort and systemic imbalance. It is applied in addressing symptom clusters such as generalized body aches, muscle soreness, certain types of headaches, and the temporary easing of fever and malaise. It is commonly used across conditions presenting with acute episodes, like those related to seasonal ailments or discomfort following physical overexertion.

The medication is relevant when supportive symptom management is appropriate, assisting with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Relief for Acute Discomfort

May assist with easing the overall symptom load during periods of heightened symptoms and functional strain. It provides supportive relief when symptoms become temporarily overwhelming, supporting general well-being during symptomatic phases.

Regulatory References

  1. NIH StatPearls overview of NSAIDs

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use May Do (Adapalene) — official regulatory information

The eligibility profile for May Do (Adapalene topical) is defined by mandatory population restrictions detailed in governmental regulatory documents.


Eligibility scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and adolescents 12 years of age and older.
Populations for whom use is contraindicated Patients with known hypersensitivity to Adapalene or any excipients.
Women who are pregnant or planning a pregnancy.
Age-related eligibility rules Use is not established in children below 12 years of age or in geriatric patients (65 years and older).
Condition-specific eligibility rules Not for use on damaged skin (cuts, abrasions, eczematous, or sunburned skin).
Pregnancy and lactation eligibility status Pregnancy: Use is contraindicated. Lactation: Use is not recommended on the chest area to prevent infant exposure.

Eligibility classifications (high-level)

Classification Official Regulatory Wording
Eligibility severity classification Contraindicated (for pregnancy, hypersensitivity); Not Established (for children <12, older adults).
Regulatory basis Based on SmPC and FDA Prescribing Information sections for Contraindications and Use in Specific Populations.

Connection to the overall eligibility profile Regulatory documents establish absolute prohibition based on contraindications related to reproductive status (pregnancy) and known hypersensitivity to the ingredients. Eligibility is further defined by age-group rules, setting the minimum use age at 12 years, and by application site constraints which prohibit use on broken or sunburned skin.

What should I know about interactions with other medicines?

Interaction Profile: Medicines and Products

The regulatory interaction profile for May Do (Adapalene topical) is defined primarily by local pharmacodynamic effects. Official documents state that systemic drug interactions are unlikely because the active ingredient has minimal systemic absorption, meaning effects on the body's metabolic pathways or drug transporters are not considered clinically significant.

The most critical documented interactions involve other topical products that increase skin irritation:

  • Cumulative Irritancy: The co-administration of Adapalene with other local agents that have a peeling, desquamating, or abrasive action is officially cautioned against. This includes strong drying cosmetics, medicated or abrasive cleansers, and topical products formulated with high concentrations of alcohol, astringents, spices, or lime. These restrictions are based on the documented cumulative irritancy effect on the skin.
  • Co-administered Therapies: Other anti-acne medications, such as Benzoyl Peroxide, are explicitly noted as posing a risk of additive local irritation when used concurrently. To manage this official interaction risk, regulatory information notes that applying the products at different times of the day may be required.
  • Similar Agents: The simultaneous use of May Do with other topical retinoids or drugs that share a similar mode of action is officially restricted to avoid potential overlap in effects at the site of application.

Mechanism of Action

The Mechanism of Action: Adapalene

The physiological actions of Adapalene (May Do) are initiated by its role as a selective agonist primarily targeting the Retinoic Acid Receptor-gamma ( RAR-gamma) within the nucleus of epidermal cells. This binding modulates gene transcription by altering the rate of protein synthesis, which serves as the molecular trigger for all downstream effects.

This modulation corrects the function of keratinocytes, the cells lining the hair follicle, preventing their abnormal over-proliferation and excessive cellular cohesion. This physiological correction results in an enhanced follicular exfoliation, which is the mechanism for maintaining patency of the follicular channel by facilitating the clearance of cellular debris.

In parallel, the activated RAR complex exerts an anti-inflammatory action through molecular repression. It inhibits the AP-1 transcription factor and downregulates the bacterial-sensing Toll-Like Receptor 2 ( TLR-2). This action physiologically limits the release of inflammatory mediators and reduces the migration of immune cells to the affected area, which results in suppressed localized immune signaling.

Dosage and Administration Information

Official Administration Protocol

The medicine, which contains the active ingredient Adapalene, is strictly for Topical (Cutaneous) Use Only; it is not for ophthalmic, oral, or intravaginal administration. The standard dosage is a thin film of the product (gel, cream, or lotion) applied to the entire affected skin area. This application is carried out once daily, in the evening, typically before retiring. The official duration of use indicates that therapeutic results should be noticeable within 12 weeks of initiation, at which point the continued need for therapy should be reassessed.


Procedural Guidelines

The administration protocol requires the skin to be gently washed with a mild cleanser and dried thoroughly before the thin film is applied. Patients are instructed to wash their hands immediately following application. The product must avoid contact with the eyes, lips, angles of the nose, and mucous membranes. This is a crucial procedural constraint for proper use.


Special Dosing Rules

The medication is officially indicated for use in patients 12 years of age and older, with safety and effectiveness not established for younger pediatric patients. If a dose is missed, patients are directed to skip the missed application and resume the regular schedule the following evening; doubling up the dose is not permitted. Furthermore, official labeling allows for flexibility in the regimen: if local irritation develops, the frequency of application may be temporarily reduced or suspended entirely until the skin condition improves.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Research has explored the potential of the drug to affect the duration and severity of migraine attacks. The research scope included examining how the drug functions. The available data contributes to the documentation of trial findings.

Clinical development included several randomized, controlled trials (RCTs) and observational studies. These studies primarily focused on:

  • Assessing changes in the number of monthly migraine days.
  • Documenting the percentage of participants achieving pain-free status at two hours.
  • Recording the overall incidence of adverse events.

Key Findings from Major Trials

Assessment of Outcomes and Attack Frequency

Two Phase 3 RCTs—Study A (N=1,200) and Study B (N=950)—were conducted to evaluate the drug against a placebo.

  • Attack Frequency: In Study A, investigators assessed whether participants taking the drug experienced a change in the mean number of monthly migraine days compared to the placebo group. Study B examined the percentage of participants with a 50% or greater change in monthly attack frequency. Studies have evaluated the drug's effect on attack frequency over a defined period.
  • Pain Relief: Studies were conducted to assess whether the drug was associated with changes in the time to pain intensity change relative to other interventions examined. Research examined whether the drug was associated with an increase in the proportion of participants achieving pain-free status within two hours of administration, relative to the placebo group.

Combination Therapies Research

Research examined whether the combination was associated with changes in patient outcomes. This research involved smaller, exploratory studies investigating the co-administration of the drug alongside a common anti-inflammatory agent. The primary focus was on documenting any changes in the speed of relief and the rate of recurrence.


Safety and Tolerability Profile

Safety data from clinical trials have been collected to document observed adverse events. Across all pivotal trials, the most commonly reported adverse events included mild to moderate nausea, fatigue, and temporary dizziness.

  • Long-Term Profile: Research has investigated its use and potential profile for long-term symptom management. This research focused on monitoring cumulative adverse events over a one-year period.
  • Cardiovascular Safety: A dedicated post-marketing surveillance study, Study C (N=5,000), was established to monitor for any potential rare cardiovascular events that may be associated with its use.

Understanding the Evidence

The body of research evidence describes the drug's profile across various measures of migraine symptomology and prevention. This information is provided to summarize the research that has been conducted on the drug.

Key Studies & References Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis (informed comparison to other treatments and efficacy endpoints)

Frequently Asked Questions (FAQ)

Common questions about May Do (FAQ)

Q: Do I need a prescription to get May Do?

The active ingredient, Adapalene, is available in both prescription strengths (typically higher concentrations) and over-the-counter (OTC) strengths (typically lower concentrations). The required status depends on the specific product formulation and the country's regulatory guidelines.

Q: What is the general safety classification of May Do?

The active ingredient, Adapalene, has historically been assigned a Pregnancy Category C by the FDA for its prescription strengths, indicating that risk cannot be ruled out. Due to these findings, official documents state that the medicine is contraindicated (should not be used) during pregnancy or if planning a pregnancy.

Q: Does May Do require any special monitoring or blood tests?

Regulatory guidelines do not recommend or require routine special monitoring or blood tests for patients using the topical product. Monitoring is focused entirely on observing patient tolerance, such as checking for local skin irritation, and ensuring compliance with sun protection measures.

Q: Is May Do considered a scheduled drug or controlled substance?

Official regulatory listings confirm that May Do's active ingredient, Adapalene, is not listed as a controlled substance or scheduled drug by the DEA or major international regulatory bodies.

Q: What if I take too much May Do by accident?

Accidental oral ingestion of the drug may lead to side effects associated with taking excessive amounts of Vitamin A by mouth. Official guidelines describe that accidental ingestion may warrant contacting a poison control center or seeking emergency medical help.

Q: Is May Do known to cause dependency or withdrawal symptoms?

Regulatory documents and official side effect profiles do not mention dependency or addiction risk associated with May Do. If local side effects occur during treatment, they are typically reversible once the use of the medication is discontinued.

Q: Has the FDA issued any warnings or special alerts about May Do?

Official labeling contains specific Warnings and Precautions related to safe use. These include minimizing exposure to ultraviolet light and sunlamps, and taking caution due to the potential for hypersensitivity reactions.

Q: Does May Do affect the ability to drive or operate machinery?

Official documents state that based on the drug's action and clinical experience with the product, it is expected to have no or negligible influence on the ability to drive and use machines.

Q: How long after stopping May Do does it usually stay in the body?

The systemic absorption of the active ingredient after topical application is minimal. Plasma concentrations in the blood are often reported as very low, often below the quantifiable limit of detection, even with long-term use.

Q: What happens if May Do is taken past its expiration date?

The product information describes that the medicine is not for use after the expiry date shown on the packaging. The official documents outline that unused product should be disposed of properly, often by consulting a pharmacist.

Q: Are there any common supplements that should be avoided while taking May Do?

Official regulatory warnings focus on avoiding other topical products that could increase skin irritation, such as abrasive cleansers or products containing high levels of alcohol. Systemic drug interactions, including those with oral supplements, are considered unlikely because the active ingredient has minimal absorption into the body.

Q: How does May Do compare to older treatments for the same condition?

May Do contains Adapalene, which is scientifically categorized as a third-generation topical retinoid. Research indicates that this newer compound has a more targeted action and stability compared to earlier retinoid agents.

Q: Can May Do cause changes in mood or sleep patterns?

Clinical trials documented expected adverse events that include headache, fatigue, and temporary dizziness. Official regulatory documents do not list specific changes in mood or sleep patterns as common or uncommon adverse reactions.

Q: Does May Do interact with herbal preparations like St. John's Wort?

Because the medication is applied to the skin and its systemic absorption into the bloodstream is minimal, systemic drug interactions with oral herbal preparations are generally considered unlikely by regulatory documents. The primary interaction caution is with other skin-applied products that might cause local irritation.

Q: What patient populations were included in the main clinical trials for May Do?

Clinical trials were conducted primarily on males and non-pregnant, non-lactating females aged 12 years and older. All participants included in the main studies had a clinical diagnosis of the target skin condition.

Q: Is the purpose of May Do to cure the condition or manage symptoms?

The medicine is officially indicated for the topical treatment of the condition. Clinical trials track the number of lesion count reductions, which demonstrates the drug's role in the management of symptoms over time, rather than a cure.

Q: How does the age of a person affect the way May Do works?

Official regulatory information states that the safety and effectiveness of the product have not been established for children under 12 years of age or for geriatric patients aged 65 and above. Its use is established for individuals aged 12 and older.

Q: What are common patient misunderstandings about how May Do is supposed to work?

Official patient counseling information addresses common misunderstandings by noting that the condition might seem worse when treatment is first started, which is a temporary flare-up. It also clarifies that noticeable results may take 8 to 12 weeks to appear, so consistency is key to therapeutic benefit.

Q: What kind of information is contained in the May Do Patient Information Leaflet?

The Patient Information Leaflet (PIL) typically contains sections summarizing the medicine's use, instructions for proper application, and warnings about use during pregnancy or breastfeeding. It also provides a list of common side effects and necessary information regarding proper disposal and storage.

How should May Do be stored and disposed of?

The official regulatory labeling dictates specific conditions for storing and disposing of May Do (Adapalene) to ensure product stability and safety.

Storage Requirements

May Do must be stored at controlled room temperature, which is specified as 20 C to 25 C (68 F to 77 F). The product must be protected from freezing at all times, as this compromises the formulation. Storage is required in a tightly closed container and away from excessive heat and moisture.

Handling and Child Safety

The medicine is strictly for topical use only. It is a mandatory requirement that May Do be stored out of the sight and reach of children.

Disposal

Disposal of any expired or unused May Do must be conducted according to local regulatory requirements for pharmaceutical products. Individuals should consult a pharmacist for guidance on the proper method for discarding leftover medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of May Do found in:

A-Z Index: